1,935 results on '"Lipton, Richard B."'
Search Results
2. Perceived but not objective measures of neighborhood safety and food environments are associated with longitudinal changes in processing speed among urban older adults
3. Sustained response to atogepant in episodic migraine: post hoc analyses of a 12-week randomized trial and a 52-week long-term safety trial
4. Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE
5. Brain effects of mild COVID-19 in healthy young adults: A pilot study
6. Preventive Treatment of Migraine
7. Pre- and post-headache phases of migraine: multi-country results from the CaMEO – International Study
8. A polygenic risk score for Alzheimer’s disease constructed using APOE-region variants has stronger association than APOE alleles with mild cognitive impairment in Hispanic/Latino adults in the U.S.
9. Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study
10. Interaction analysis of ancestry-enriched variants with APOE-ɛ4 on MCI in the Study of Latinos-Investigation of Neurocognitive Aging
11. Availability of healthy foods, fruit and vegetable consumption, and cognition among urban older adults
12. Validation and meaningful within-patient change in work productivity and activity impairment questionnaire (WPAI) for episodic or chronic migraine
13. Health State Utility Mapping of Rimegepant for the Preventive Treatment of Migraine: Double-Blind Treatment Phase and Open Label Extension (BHV3000-305)
14. Ubrogepant for the treatment of migraine attacks during the prodrome: a phase 3, multicentre, randomised, double-blind, placebo-controlled, crossover trial in the USA
15. Older adults' self-reported prospective memory lapses in everyday life: Connections to inflammation and gender
16. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial
17. Characterizing age- and sex-related differences in brain structure among middle-aged and older Hispanic/Latino adults in the study of Latinos- investigation of neurocognitive aging magnetic resonance imaging (SOL-INCA MRI)
18. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial
19. The Association Between the Occurrence of Common Treatment-Emergent Adverse Events and Efficacy Outcomes After Lasmiditan Treatment of a Single Migraine Attack: Secondary Analyses from Four Pooled Randomized Clinical Trials
20. Lasmiditan for Patients with Migraine and Contraindications to Triptans: A Post Hoc Analysis
21. Predictors of treatment-response to acute prescription medications in migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
22. Repetitive soccer heading adversely impacts short-term learning among adult women
23. Depressive symptoms mediate the relationship between diabetes and cognitive performance in a community-based sample of older adults
24. Reliabilities of Intra-Individual Mean and Intra-Individual Variability of Self-Reported Pain Derived From Ecological Momentary Assessments: Results From the Einstein Aging Study
25. Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials
26. Eptinezumab treatment initiated during a migraine attack is associated with meaningful improvement in patient-reported outcome measures: secondary results from the randomized controlled RELIEF study
27. Functionality, satisfaction, and global impression of change with ubrogepant for the acute treatment of migraine in triptan insufficient responders: a post hoc analysis of the ACHIEVE I and ACHIEVE II randomized trials
28. Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency
29. Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
30. Inflammatory biomarkers and motoric cognitive risk syndrome: Multicohort survey
31. Blood Pressure, Antihypertensive Use, and Late-Life Alzheimer and Non-Alzheimer Dementia Risk: An Individual Participant Data Meta-Analysis.
32. The headache research priorities: Research goals from the American Headache Society and an international multistakeholder expert group.
33. Machine learning identifies factors most associated with seeking medical care for migraine: Results of the OVERCOME (US) study.
34. Situational prevention: Pharmacotherapy during periods of increased risk for migraine attacks.
35. Efficacy and Safety of Rimegepant 75 mg Oral Tablet, a CGRP Receptor Antagonist, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial.
36. Elevated Blood Homocysteine Increases the Risk of Incident Motoric Cognitive Risk Syndrome: A Two-Cohort Study.
37. Characterizing neck pain during headache among people with migraine: Multicountry results from the Chronic Migraine Epidemiology and Outcomes – International (CaMEO‐I) cross‐sectional study.
38. Sustained benefits of onabotulinumtoxinA treatment in chronic migraine: An analysis of the pooled Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) randomized controlled trials.
39. Glycemic Control, Cognitive Aging, and Impairment Among Diverse Hispanic/Latino Individuals: Study of Latinos-Investigation of Neurocognitive Aging (Hispanic Community Health Study/Study of Latinos).
40. Mapping Migraine-Specific Quality of Life to Health State Utilities in Patients Receiving Rimegepant
41. Under Treatment of High-Risk TIA Patients with Clopidogrel-Aspirin in the Emergency Setting
42. A coordinated analysis of the associations among personality traits, cognitive decline, and dementia in older adulthood
43. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial
44. Framing potential for adverse effects of repetitive subconcussive impacts in soccer in the context of athlete and non-athlete controls
45. Education and the moderating roles of age, sex, ethnicity and apolipoprotein epsilon 4 on the risk of cognitive impairment
46. Reliability and validity of the 6-item Headache Impact Test in chronic migraine from the PROMISE-2 study
47. Lifestyle and incident dementia: A COSMIC individual participant data meta‐analysis.
48. Association Between Hypertensive Disorders of Pregnancy and Interval Neurocognitive Decline.
49. Cardiovascular disease risk exacerbates brain aging among Hispanic/Latino adults in the SOL-INCA-MRI Study.
50. Characterizing gaps in the preventive pharmacologic treatment of migraine: Multi‐country results from the CaMEO‐I study.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.